

Tessa Gargett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8958726/publications.pdf>

Version: 2024-02-01

28
papers

1,293
citations

471509

17
h-index

526287

27
g-index

32
all docs

32
docs citations

32
times ranked

2370
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. <i>Frontiers in Immunology</i> , 2022, 13, 850226.	4.8	13
2	Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. <i>Cancer Research Communications</i> , 2022, 2, 706-724.	1.7	3
3	The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy. <i>Cells</i> , 2021, 10, 607.	4.1	32
4	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	3.7	21
5	Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. <i>Molecular Imaging and Biology</i> , 2021, 23, 914-928.	2.6	3
6	Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1191.	3.8	34
7	Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 383-386.	1.1	6
8	Clinical chimeric antigen receptor T cell therapy: a new and promising treatment modality for glioblastoma. <i>Clinical and Translational Immunology</i> , 2019, 8, e1050.	3.8	33
9	Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. <i>Cytotherapy</i> , 2019, 21, 593-602.	0.7	30
10	Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 1749-1755.	7.0	18
11	Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. <i>Biochemical Society Transactions</i> , 2018, 46, 391-401.	3.4	26
12	Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1461-1472.	4.2	68
13	Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study". <i>Leukemia Research</i> , 2017, 55, 55-57.	0.8	3
14	GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells <i>in vitro</i> . <i>Clinical and Translational Immunology</i> , 2016, 5, e119.	3.8	30
15	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. <i>Molecular Therapy</i> , 2016, 24, 1135-1149.	8.2	281
16	Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. <i>Cytotherapy</i> , 2015, 17, 487-495.	0.7	90
17	BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro. <i>Journal of Immunotherapy</i> , 2015, 38, 12-23.	2.4	32
18	Abstract 3159: In vitro characterization of third-generation chimeric antigen receptor T cells directed toward GD2-expressing and BRAF-inhibitor resistant melanoma target cells. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
19	The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. <i>Frontiers in Pharmacology</i> , 2014, 5, 235.	3.5	280
20	Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2679-2683.	3.3	14
21	Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. <i>Clinical and Translational Immunology</i> , 2014, 3, e18.	3.8	19
22	DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. <i>European Journal of Immunology</i> , 2014, 44, 1992-2002.	2.9	20
23	Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. <i>Virus Research</i> , 2014, 192, 25-33.	2.2	6
24	A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. <i>Vaccine</i> , 2014, 32, 3409-3416.	3.8	17
25	Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. <i>Immunology and Cell Biology</i> , 2014, 92, 359-367.	2.3	29
26	Genome-Wide Identification of Human FOXP3 Target Genes in Natural Regulatory T Cells. <i>Journal of Immunology</i> , 2010, 185, 1071-1081.	0.8	128
27	Robust, Reversible Gene Knockdown Using a Single Lentiviral Short Hairpin RNA Vector. <i>Human Gene Therapy</i> , 2010, 21, 1005-1017.	2.7	32
28	Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells. <i>Journal of Leukocyte Biology</i> , 2009, 85, 445-451.	3.3	24